Stereotaxis Inc. (STXS) Investor Presentation - Slideshow

Company Overview - Stereotaxis is a global leader in robotic technology for minimally invasive endovascular surgery[4] - The company focuses on the electrophysiology market, estimated at over $6 billion, with an annual total addressable market (TAM) exceeding $10 billion[4] - Stereotaxis has a solid financial foundation with $40 million in cash and no debt, and operations are near breakeven[4] Benefits of Robotic Magnetic Navigation (RMN) - RMN offers 1mm precision, tip stability, and extended reach in endovascular procedures[17] - RMN provides radiation protection and intuitive navigation for physicians[17] - Clinical data indicates a 36% average reduction in radiation exposure with RMN compared to manual cardiac ablation[19, 61] Clinical Outcomes - A comprehensive review of clinical literature shows a 72% average reduction in major adverse events with robotic navigation[57] - Studies show that acute efficacy rates are high with robotic navigation, reaching 91.86% in some studies[67, 69] - Long-term efficacy studies demonstrate a 72.64% freedom from recurrence rate with robotic navigation[72, 73] Commercial and Innovation Strategy - The company has an established commercial infrastructure and is focused on strategic innovation[31, 34] - Stereotaxis is expanding into accessible robotics, ablation catheters, and broader endovascular indications, targeting a $10 billion+ TAM[50] - The company is pursuing geographic expansion through strategic collaborations, including a collaboration with MicroPort EP for leadership in China[50]